Dynavax Technologies Corporation (NASDAQ:DVAX) shares, rose in value on Friday, June 11, with the stock price down by -3.68% to the previous day’s close as strong demand from buyers drove the stock to $8.95.
Actively observing the price movement in the recent trading, the stock is buoying the session at $9.29, falling within a range of $9.085 and $9.56. Referring to stock’s 52-week performance, its high was $12.44, and the low was $3.58. On the whole, DVAX has fluctuated by 23.54% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.05, which is expected to increase to $0.07 for fiscal year $0.54 and then to about $0.53 by fiscal year 2022. Data indicates that the EPS growth is expected to be 172.00% in 2022, while the next year’s EPS growth is forecast to be -1.90%.
Analysts have estimated the company’s revenue for the quarter at $41.59 million, with a low estimate of $27.79 million and a high estimate of $60.28 million. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $338.14 million, representing an increase of 626.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that DVAX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
4 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 4 recommend it as a Buy and 0 called the DVAX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of DVAX currently trading nearly 9.31% and -1.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.92, while the 7-day volatility ratio is showing 4.30% which for the 30-day chart, stands at 4.57%. Furthermore, Dynavax Technologies Corporation (DVAX)’s beta value is 1.21, and its average true range (ATR) is 0.46. The company’s stock has been forecasted to trade at an average price of $18.67 over the course of the next 52 weeks, with a low of $16.00 and a high of $20.00. Based on these price targets, the low is -78.77% off current price, whereas the price has to move -123.46% to reach the yearly target high. Additionally, analysts’ median price of $20.00 is likely to be welcomed by investors because it represents a decrease of -123.46% from the current levels.
Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.
Add them to your watchlist before they take off!
A comparison of Dynavax Technologies Corporation (DVAX) with its peers suggests the former has fared considerably weaker in the market. DVAX showed an intraday change of -3.68% in today’s session so far, and over the past year, it grew by 56.00%%. In comparison, AstraZeneca PLC (AZN) has moved lower at -0.10% today and is up 9.69% over the past 12 months. On the other hand, the price of Biogen Inc. (BIIB) has fallen -2.67% today. The stock, however, is off 41.18% from where it was a year ago. Additionally, there is a loss of -1.56% for Pfizer Inc. (PFE) in recent trading while the stock has seen an overall depriciation of 19.50%% over the past year. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost -0.02%. Meanwhile, the Dow Jones Industrial Slipped by -0.12%.
Data on historical trading for Dynavax Technologies Corporation (NASDAQ:DVAX) indicates that the trading volumes over the past 10 days have averaged 1.68 million and over the past 3 months, they’ve averaged 2.77 million. According to company’s latest data on outstanding shares, there are 112.03 million shares outstanding.
Nearly 0.30% of Dynavax Technologies Corporation’s shares belong to company insiders and institutional investors own 74.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 17.66 million shares as on May 27, 2021, resulting in a short ratio of 6.04. According to the data, the short interest in Dynavax Technologies Corporation (DVAX) stood at 15.41% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 16.08 million. The stock has risen by 108.76% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DVAX stock heading into the next quarter.